Tourmaline Bio highlights positive phase 2 pacibekitug data

2 hours ago 1

Tourmaline Bio (NASDAQ:TRML) on Sunday presented additional data from its ongoing Phase 2 TRANQUILITY trial of Pacibekitug in a poster presentation at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain.

The data highlights the consistency of reduction

Recommended For You

More Trending News

Read Entire Article